---
figid: PMC4463189__JCI76094.f3
figtitle: Targeting cancer with kinase inhibitors
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC4463189
filename: JCI76094.f3.jpg
figlink: /pmc/articles/PMC4463189/figure/F3/
number: F3
caption: Dual blockade within the MAPK pathway or between the MAPK and parallel PI3K
  pathways improves clinical outcome by reducing compensatory signaling and delaying
  the onset of resistance. Mut, mutation; OE, overexpression; LOH, loss of heterozygosity;
  ↓Exp, decreased expression.
papertitle: Targeting cancer with kinase inhibitors.
reftext: Stefan Gross, et al. J Clin Invest. 2015 May 1;125(5):1780-1789.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9492187
figid_alias: PMC4463189__F3
figtype: Figure
redirect_from: /figures/PMC4463189__F3
ndex: 7ea1031d-def0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4463189__JCI76094.f3.html
  '@type': Dataset
  description: Dual blockade within the MAPK pathway or between the MAPK and parallel
    PI3K pathways improves clinical outcome by reducing compensatory signaling and
    delaying the onset of resistance. Mut, mutation; OE, overexpression; LOH, loss
    of heterozygosity; ↓Exp, decreased expression.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Ras64B
  - Ras85D
  - Akt
  - Dsor1
  - rl
  - Mtor
  - Tor
  - foxo
  - MMUT
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - AKT1
  - AKT2
  - AKT3
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - MTOR
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Cobimetinib
  - Cancer
---
